SAM
AVDL

Sectoral Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Sectoral Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,218
Closed -$67K – 108
2018
Q3 		$67K Buy
+15,218
New +$82.2K 0.01% 163

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Sectoral Asset Management's AVDL Position: Q4 2018 in Review

Sectoral Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2018, closing a stake of 15,218 shares — an estimated $67K sold.

Sectoral Asset Management first reported a position in AVDL in Q3 2018 and held it in 1 quarter. The position peaked at $67K in Q3 2018. 59 funds tracked by Wall St. Rank hold AVDL as of Q4 2018.

  • Sectoral Asset Management reported no remaining Avadel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Sectoral Asset Management sold 15,218 Avadel Pharmaceuticals shares in Q4 2018, an estimated $67K.
  • Sectoral Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Sectoral Asset Management's Avadel Pharmaceuticals position peaked at $67K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2018.

Based on Sectoral Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.